Oramed (ORMP) CFO Avraham Gabay Receives Restricted Stock Award

What Happened

Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals, was granted a restricted stock award for 209,291 shares on September 24, 2026. The Form 4 reports the grant (transaction code A); no purchase price or total dollar value is reported on the filing.

Key Details

• Transaction date: 2026-09-24 (Form 4 filed 2026-09-25; filing appears timely).
• Transaction type/code: Award (A) — restricted stock award of 209,291 shares.
• Price/value: N/A on the Form 4; fair market value or total grant value is not disclosed in the filing.
• Vesting: 40% vests on the grant date; the remaining 60% vests in eight substantially equal quarterly installments over the 24 months following the grant, subject to continued service. Unvested shares are subject to forfeiture under the award agreement and the Plan (see footnote F1).
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnotes: F1 describes the grant and vesting schedule (see above). No 10b5-1 plan, tax-withholding sale, or other special instructions are reported in the provided details.

Context

A restricted stock award is compensation, not a market purchase or sale, and vests over time contingent on continued service. Such grants are common executive compensation and do not by themselves indicate a near-term buy/sell signal.